908 Devices MASS Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 908 Devices in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: 908 Devices’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about 908 Devices's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 908 Devices's business segments — research and development expense?
- 908 Devices (MASS) reported business segments — research and development expense of $3.47M in Q1 2026.
- How has 908 Devices's business segments — research and development expense changed year-over-year?
- 908 Devices's business segments — research and development expense decreased by 9.3% year-over-year, from $3.83M to $3.47M.
- What is the long-term trend for 908 Devices's business segments — research and development expense?
- Over 2 years (2023 to 2025), 908 Devices's business segments — research and development expense has grown at a -15.7% compound annual growth rate (CAGR), from $21.9M to $15.58M.
- What does business segments — research and development expense mean?
- This metric tracks the investment in innovation, engineering, and the development of new point-of-need mass spectrometry technologies. For a medical device company, this spending is critical for maintaining a competitive edge and expanding product capabilities. It reflects the company's long-term commitment to product pipeline growth and technological advancement.